Free tool
FAERS Monitor: Invanz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021337 or its brand name (Invanz, Ertapenem Sodium). Reports on generic versions are filed under their own applications.
Reports
7,465
Serious
6,366
85% of reports
Hospitalization
3,473
Death reported
639
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,161
- macular degeneration808
- off label use539
- pyrexia467
- confusional state441
- product use in unapproved indication434
- nausea397
- pain345
- weight decreased274
- malaise271
- anaemia268
- hallucination266
- abdominal pain244
- headache239
- seizure232
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 115 |
| 2005 | 60 |
| 2006 | 93 |
| 2007 | 117 |
| 2008 | 125 |
| 2009 | 103 |
| 2010 | 117 |
| 2011 | 138 |
| 2012 | 246 |
| 2013 | 287 |
| 2014 | 279 |
| 2015 | 347 |
| 2016 | 318 |
| 2017 | 284 |
| 2018 | 425 |
| 2019 | 429 |
| 2020 | 483 |
| 2021 | 768 |
| 2022 | 633 |
| 2023 | 585 |
| 2024 | 589 |
| 2025 | 538 |
| 2026 | 386 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,694 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| macular degenerationSignal | 808 | 204.3 | 191.0 | 152,348 |
| hallucinationSignal | 266 | 10.0 | 8.9 | 2,139 |
| confusional stateSignal | 441 | 7.7 | 7.0 | 2,580 |
| seizureSignal | 232 | 5.7 | 5.0 | 890 |
| product use in unapproved indicationSignal | 434 | 4.9 | 4.5 | 1,374 |
| anaemiaSignal | 268 | 4.0 | 3.5 | 595 |
| pyrexiaSignal | 467 | 3.8 | 3.5 | 978 |
| abdominal painSignal | 244 | 3.0 | 2.6 | 317 |
| weight decreasedSignal | 274 | 2.8 | 2.5 | 311 |
| drug ineffectiveSignal | 1,161 | 2.5 | 2.4 | 1,095 |
| malaise | 271 | 1.7 | 1.5 | 87 |
| off label use | 539 | 1.7 | 1.6 | 174 |
| pain | 345 | 1.6 | 1.4 | 76 |
| nausea | 397 | 1.4 | 1.3 | 49 |
| headache | 239 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.